Stroke:乙酰水杨酸等的应用与AMI患者短期内更少发生缺血性卒中相关

2014-05-16 寒林 译 中国医学论坛报手机报

一项研究表明,1998年~2008年期间,瑞典的急性心肌梗死(AMI)患者起病30天内缺血性卒中的发生率下降,这与10年期间乙酰水杨酸、P2Y12抑制剂、他汀及经皮冠状动脉介入治疗(PCI)的应用相关。文章发表于《卒中》(Stroke 2014,45:1324)杂志。 研究分析了173233例AMI患者,其中3571例(2.1%)患者在AMI起病后30天内发生缺血性卒中。与1998年~2000年

一项研究表明,1998年~2008年期间,瑞典的急性心肌梗死(AMI)患者起病30天内缺血性卒中的发生率下降,这与10年期间乙酰水杨酸、P2Y12抑制剂、他汀及经皮冠状动脉介入治疗(PCI)的应用相关。文章发表于《卒中》(Stroke 2014,45:1324)杂志。

研究分析了173233例AMI患者,其中3571例(2.1%)患者在AMI起病后30天内发生缺血性卒中。与1998年~2000年相比,2007年~2008年AMI患者起病30天内缺血性卒中的发生率显著降低(2.0%对2.2%,P=0.02)。与缺血性卒中发生风险增加相关的独立预测因素包括了年龄、女性、卒中病史、糖尿病、心房颤动、院内心力衰竭临床症状、ST段抬高型心肌梗死(STEMI)、冠状动脉旁路移植术及出院时血管紧张素转换酶抑制剂(ACEI)的应用,而PCI、溶栓治疗及乙酰水杨酸、他汀、P2Y12抑制剂的应用则是与缺血性卒中发生风险下降相关的独立预测因素。








版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952312, encodeId=42021952312bd, content=<a href='/topic/show?id=62252346884' target=_blank style='color:#2F92EE;'>#乙酰水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23468, encryptionId=62252346884, topicName=乙酰水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 30 07:08:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805987, encodeId=89eb180598eb5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 03 05:08:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892610, encodeId=affa1892610d5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 30 03:08:00 CST 2014, time=2014-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984044, encodeId=11c7198404401, content=<a href='/topic/show?id=e3f464183db' target=_blank style='color:#2F92EE;'>#水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64183, encryptionId=e3f464183db, topicName=水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Apr 17 10:08:00 CST 2015, time=2015-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1952312, encodeId=42021952312bd, content=<a href='/topic/show?id=62252346884' target=_blank style='color:#2F92EE;'>#乙酰水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23468, encryptionId=62252346884, topicName=乙酰水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 30 07:08:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805987, encodeId=89eb180598eb5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 03 05:08:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892610, encodeId=affa1892610d5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 30 03:08:00 CST 2014, time=2014-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984044, encodeId=11c7198404401, content=<a href='/topic/show?id=e3f464183db' target=_blank style='color:#2F92EE;'>#水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64183, encryptionId=e3f464183db, topicName=水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Apr 17 10:08:00 CST 2015, time=2015-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1952312, encodeId=42021952312bd, content=<a href='/topic/show?id=62252346884' target=_blank style='color:#2F92EE;'>#乙酰水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23468, encryptionId=62252346884, topicName=乙酰水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 30 07:08:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805987, encodeId=89eb180598eb5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 03 05:08:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892610, encodeId=affa1892610d5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 30 03:08:00 CST 2014, time=2014-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984044, encodeId=11c7198404401, content=<a href='/topic/show?id=e3f464183db' target=_blank style='color:#2F92EE;'>#水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64183, encryptionId=e3f464183db, topicName=水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Apr 17 10:08:00 CST 2015, time=2015-04-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1952312, encodeId=42021952312bd, content=<a href='/topic/show?id=62252346884' target=_blank style='color:#2F92EE;'>#乙酰水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23468, encryptionId=62252346884, topicName=乙酰水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 30 07:08:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805987, encodeId=89eb180598eb5, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jul 03 05:08:00 CST 2014, time=2014-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892610, encodeId=affa1892610d5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 30 03:08:00 CST 2014, time=2014-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984044, encodeId=11c7198404401, content=<a href='/topic/show?id=e3f464183db' target=_blank style='color:#2F92EE;'>#水杨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64183, encryptionId=e3f464183db, topicName=水杨酸)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Apr 17 10:08:00 CST 2015, time=2015-04-17, status=1, ipAttribution=)]